Document is current

Any future updates will be listed below

On the efficacy and safety of rituximab therapy in patients with systemic sclerosis disease: missing points, bottlenecks, over-exaggeration, and discrepancies—comments on the article by Moradzadeh et al.

Crossref DOI link: https://doi.org/10.1007/s10067-021-05786-5

Published Online: 2021-07-16

Published Print: 2021-10

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark